Citable company snapshot
Insmed Incorporated's latest SEC-sourced 2026-03-31 period shows $305.96M in revenue and $-163.56M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $305.96M | $263.84M | +16.0% |
| xbrl:GrossProfit | Sep 30, 2020 | $33.02M | $32.55M | +1.5% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $-153.32M | $-319.75M | +52.0% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $-163.56M | $-328.49M | +50.2% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $-222.74M | $-247.60M | +10.0% |
| Free Cash Flow (computed) | Mar 31, 2026 | $-226.22M | $-264.19M | +14.4% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 7, 2026; accession 0001104506-26-000032.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
